Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — 20th Annual Needham Virtual Healthcare Conference (April 2021)
24 slides from Sutro Biopharma's conference presentation, Apr 15, 2021
Slide 1: 20th Annual Needham Virtual Healthcare Conference
20th Annual Needham Virtual Healthcare Conference April 15, 2021 Sutro Biopharma NASDAQ: STRO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Pioneer and Leader in Cell-Free Technology
Pioneer and Leader in Cell-Free Technology Expanding cell-free beyond ADCs Additional value creation 1 Multiple ADC through programs spinout Building showcasing ecosystem platform through breadth 1 New strategic modalities and Establish partnerships extended cell-free 1 value creation ecosystem 1 1
Slide 4: Industry Leading Cell-Free Protein Synthesis Platform
Industry Leading Cell-Free Protein Synthesis Platform GMP production yields consistent and scalable end-products IgG with Non- Grow Cells Cellular Cell-Free Protein Natural Amino Linker-Warhead Homogenous from E. Coli Cell Lysis Extract Synthesis Acids Click Chemistry ADC 1 2 3 4 5 6 7 Specific to p
Slide 5: Advantages of Precision Protein Therapeutics
Advantages of Precision Protein Therapeutics Homogenous, precisely designed complex biologics with optimized performance Challenges in Traditional Cell-Based Complex Advantages of Sutro’s Cell-Free Synthesis Biologics Discovery and Manufacturing Platform for Best-in-Class Biologics Performance Perfo
Slide 6: Cell-Free Platform is a Proven IND Engine
Cell-Free Platform is a Proven IND Engine Four product candidates in the clinic and other late-stage discovery programs in various modalities Program Discovery Preclinical Phase 1/1b Phase 2/3 Commercial Rights STRO-002 FolRα-Targeting ADC Ovarian and Endometrial Cancer STRO-001 Lymphomas: DLBCL, Ma
Slide 7: FolRα-Targeting ADC
STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 8: Potential Best-in-Class ADC for Ovarian and Endometrial Cancers
STRO 002 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers FolRα targeting ADC with potentially dual mechanism of action 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate- receptor alpha (FolRα): Y180 1• FolRα is ove
Slide 9: STRO-002 GM1 Phase 1 Two-Part Design
STRO 002 STRO-002 GM1 Phase 1 Two-Part Design Dose-escalation has been completed and data was presented December 2020 Part 1: Dose-Escalation Cohort in Ovarian All Patients Baseline Characteristic N=39 All-Comers STRO-002 6.4 mg/kg 61 years Ovarian Cancer Median age N=39 (range: 48–79) STRO-002 3.9
Slide 10: STRO-002 Was Generally Well Tolerated
STRO 002 STRO-002 Was Generally Well Tolerated 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal Dose Levels in Dose-Escalation Common TEAEs > 25% By Grade (2) Overall All Patients All Safety Grade 1 Grade 2 Grade 3 Grade 4 Dose Levels (Q3W) (N=39) (N=39) Evaluable Patients N (%)
Slide 11: Tumor Reduction Observed in Majority of Patients
STRO 002 Tumor Reduction Observed in Majority of Patients 10 patients met criteria for response Maximum Change (1) in Tumor Target Lesions 20% Objective RECIST- Response Evaluable 0% per RECIST Population 1.1 (N=31) Responders 10 -30% Partial Response PRu PRu PRu CR (2) 1 PRu Starting Dose, Q3W PR P
Slide 12: Tumor Regression and Control Over Time
STRO 002 Tumor Regression and Control Over Time Deepening of responses over time and others with disease control remaining on study Change in Sum of Diameters for Target Lesions Over Time (N=31) Change from baseline (%) 20 0 Best overall response PD SD PRu -30 PR CR Treatment ongoing as of October 3
Slide 13: Clinical Benefit Seen in Heavily Pre-Treated Patient Population
STRO 002 Clinical Benefit Seen in Heavily Pre-Treated Patient Population Disease control rate of 74% at 12 weeks in RECIST-evaluable population Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) CR Dose Level PR 2.9 mg/kg 3.5 mg/kg CR Individual patients treated with STRO-002 PR
Slide 14: FolRα Expression by Immunohistochemistry
STRO 002 FolRα Expression by Immunohistochemistry (1) In emerging data, responses and anti-tumor activity observed across various FolRα expression levels Individual Patients (N=13) (Ventana FOLR1 assay) 300 Best Overall Response (BOR) H-score 200 PR PRu 100 SD PD 0 FOLR1 PS2+ Score: Weak/Absent Expr
Slide 15: Path Forward for STRO-002 Clinical Development
STRO 002 Path Forward for STRO-002 Clinical Development Next steps for moving towards registration-directed study Part 2: Dose-Expansion Cohorts (Ovarian & Endometrial) First patient for Determine optimal efficacious ovarian cohort dose that is well-tolerated and All-Comers Ovarian Cancer N≈20 STRO-
Slide 16: CD74-Targeting ADC
STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 17: Potential First-in-Class Molecule for Patients with NHL and MM
STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: 1• CD74 is expresse
Slide 18: STRO-001-BCM1 Study Design and Updates
STRO 001 STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose-Escalation Study NHL Cohort Update at ASH 2020 Cohort A R/R multiple myeloma RP2D A total of 21 patients have been treated with STRO-001 (N = 30) and 18 patients were
Slide 19: ASH 2020 Update in NHL Cohort
STRO 001 ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) Patients With ≥1 Event, n (%) TEAEs by Grade, Age, median (range), years 64.5 (21–82) Occurring in ≥ 15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagn
Slide 20: Encouraging Interim Treatment Duration and Responses
STRO 001 Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Best Doses Demographics Prior Therapies treated with STRO-001 (N=18)(1) PR Response received, level and Diagnosis Individual
Slide 21: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer
Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Bispecific Antibody Conjugated Antibody Cytokine Derivative Prodrug Cytokine Modality Immune Cell Engager ADC or ISAC iADC Bispecific ADC Derivative Tar
Slide 22: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources Projected cash runway into $326.5M in cash, cash equivalents & 2H 2023 , marketable securities not including potential monetization of as of year-end 2020 Vaxcyte shares or future BD ~1.6M shares Funding received from our c
Slide 23: Driving Value Through Advancing Programs
Driving Value Through Advancing Programs Multiple opportunities to impact value into 2021 and beyond Program Indication Milestone Anticipated Timing Updated dose-escalation data 1H 2021 Initial dose-expansion data 2H 2021 STRO-002 Ovarian Cancer Initiate combination study 2H 2021 FolRα ADC EOP1/2 FD
Slide 24: Experienced Leadership Team
Experienced Leadership Team Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Scientific Officer MD, MS, FACP Chief Financial Officer Chief Medical Officer William Newell, JD Chief Executive Officer and Member of the Board of Directors Shabbir Anik, PhD Linda Fitzpatrick Nicki Vasquez, PhD Chief Tec
Sutro Biopharma — 20th Annual Needham Virtual Healthcare Conference (April 2021) on 6ix